Amarin Corporation plcAMRN

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Ireland · amarincorp.com

Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease burden and advancing cardiovascular science, marketing VASCEPA/VAZKEPA (icosapent ethyl), an FDA-approved treatment derived from eicosapentaenoic acid. It commercializes the drug directly in the U.S. and through an indirect distribution network covering close to 100 markets worldwide.

Key ratios

FCF / Sales

8.4%TTM

2025 3.1%2024 -13.6%2023 2.2%

Net margin

-14.6%TTM

2025 -18.2%2024 -36.0%2023 -19.3%

ROA

-1.3%2025

2024 -4.6%2023 -1.3%

ROE

-6.0%TTM

2025 -8.2%2024 -15.8%2023 -10.3%

Revenue growth

-15.1%TTM

2025 -6.6%2024 -25.5%2023 -16.9%

Recent news

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 2026-08-31 · GlobeNewswire

Track AMRN in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer